Zobrazeno 1 - 10
of 197
pro vyhledávání: '"Mark, Wunderlich"'
Autor:
Ashley E. Culver-Cochran, Aishlin Hassan, Kathleen Hueneman, Kwangmin Choi, Averil Ma, Brett VanCauwenbergh, Eric O’Brien, Mark Wunderlich, John P. Perentesis, Daniel T. Starczynowski
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Acute myeloid leukemia (AML) is a deadly hematopoietic malignancy. Although many patients achieve complete remission with standard induction therapy, a combination of cytarabine and anthracycline, ~40% of patients have induction failure. The
Externí odkaz:
https://doaj.org/article/356edbda75cf4decb86051b5cb964a65
Autor:
Vladimir Riabov, Qingyu Xu, Nanni Schmitt, Alexander Streuer, Guo Ge, Lyndsey Bolanos, Mark Wunderlich, Johann-Christoph Jann, Alina Wein, Eva Altrock, Marie Demmerle, Sanjay Mukherjee, Abdullah Mahmood Ali, Felicitas Rapp, Verena Nowak, Nadine Weimer, Julia Obländer, Iris Palme, Melda Göl, Ahmed Jawhar, Ali Darwich, Patrick Wuchter, Christel Weiss, Azra Raza, Jason M. Foulks, Daniel T. Starczynowski, Feng-Chun Yang, Georgia Metzgeroth, Laurenz Steiner, Mohamad Jawhar, Wolf-Karsten Hofmann, Daniel Nowak
Publikováno v:
Haematologica, Vol 109, Iss 5 (2023)
Inhibitors of anti-apoptotic BCL-2 family proteins in combination with chemotherapy and hypomethylating agents (HMA) are promising therapeutic approaches in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib, a cycl
Externí odkaz:
https://doaj.org/article/587fe7bf73e84c44b2b804ab4433a656
Autor:
Xiaoxiao Liu, Naru Sato, Tomohiro Yabushita, Jingmei Li, Yuhan Jia, Moe Tamura, Shuhei Asada, Takeshi Fujino, Tsuyoshi Fukushima, Taishi Yonezawa, Yosuke Tanaka, Tomofusa Fukuyama, Akiho Tsuchiya, Shiori Shikata, Hiroyuki Iwamura, Chieko Kinouchi, Kensuke Komatsu, Satoshi Yamasaki, Tatsuhiro Shibata, Atsuo T Sasaki, Janet Schibler, Mark Wunderlich, Eric O'Brien, Benjamin Mizukawa, James C Mulloy, Yuki Sugiura, Hitoshi Takizawa, Takuma Shibata, Kensuke Miyake, Toshio Kitamura, Susumu Goyama
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 1, Pp n/a-n/a (2023)
Abstract Inosine monophosphate dehydrogenase (IMPDH) is a rate‐limiting enzyme in de novo guanine nucleotide synthesis pathway. Although IMPDH inhibitors are widely used as effective immunosuppressants, their antitumor effects have not been proven
Externí odkaz:
https://doaj.org/article/80b4174013704cb29ecfb11251a79951
Autor:
Kaylin G. Earnest, Erin M. McConnell, Eman M. Hassan, Mark Wunderlich, Bahareh Hosseinpour, Bianca S. Bono, Melissa J. Chee, James C. Mulloy, William G. Willmore, Maria C. DeRosa, Edward J. Merino
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Current classes of cancer therapeutics have negative side effects stemming from off-target cytotoxicity. One way to avoid this would be to use a drug delivery system decorated with targeting moieties, such as an aptamer, if a targeted aptame
Externí odkaz:
https://doaj.org/article/17d8b5d0007c474daed087ef61f4e1db
Autor:
Yuan Li, Yi Zheng, Phuong Nguyen, Ting Wen, Anil G Jegga, Khalid W Kalim, Jun-Qi Yang, Mark Wunderlich, Vishnu Modur, Ashley Kuenzi Davis, Ravinder Verma, Qing Richard Lu, Fukun Guo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Background Cancer immunotherapy has taken center stage in cancer treatment. However, the current immunotherapies only benefit a small proportion of patients with cancer, necessitating better understanding of the mechanisms of tumor immune evasion and
Externí odkaz:
https://doaj.org/article/0a852aedcfe146eb8f5e7e1f97e9c4cf
Autor:
Svetlana S. Itskovich, Arun Gurunathan, Jason Clark, Matthew Burwinkel, Mark Wunderlich, Mikaela R. Berger, Aishwarya Kulkarni, Kashish Chetal, Meenakshi Venkatasubramanian, Nathan Salomonis, Ashish R. Kumar, Lynn H. Lee
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
The alternative splicing regulator MBNL1 is overexpressed in MLL-rearranged leukaemia. Here, the authors show that MBNL1-mediated alternative splicing leads to a specific splicing profile in MLL-rearranged leukaemia and loss or inhibition of MBNL1 im
Externí odkaz:
https://doaj.org/article/1b153388c9a248a7aa9ef84624fc49dd
Autor:
Huanhuan Zhao, Jun Lu, Tong Yan, Fei Han, Jie Sun, Xiaolin Yin, Liting Chen, Chao Shen, Mark Wunderlich, Weina Yun, Lingling Yang, Liyun Chen, Dan Su, Stefan K. Bohlander, Fudi Wang, James C. Mulloy, Chong Li, Jianjun Chen, He Huang, Xi Jiang
Publikováno v:
Cell Reports, Vol 38, Iss 4, Pp 110253- (2022)
Summary: Acute myeloid leukemia (AML) is a genetically heterogeneous and frequently fatal malignancy. The ten-eleven translocation (TET)-mediated DNA demethylation is known to be critically associated with AML pathogenesis. Through chemical compound
Externí odkaz:
https://doaj.org/article/b5b81ae881734f6aa8321345573a6fe4
Autor:
Yasutaka Hayashi, Susumu Goyama, XiaoXiao Liu, Moe Tamura, Shuhei Asada, Yosuke Tanaka, Tomofusa Fukuyama, Mark Wunderlich, Eric O’Brien, Benjamin Mizukawa, Satoshi Yamazaki, Akiko Matsumoto, Satoshi Yamasaki, Tatsuhiro Shibata, Koichi Matsuda, Goro Sashida, Hitoshi Takizawa, Toshio Kitamura
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
MDM2 is frequently overexpressed in acute myeloid leukaemia leading to p53 inactivation. Here, the authors are demonstrating that an inhibitor of p53-MDM2 interaction, DS-5272, induce in vivo tumour regression through immune response regulation.
Externí odkaz:
https://doaj.org/article/ac8963cff5ca454687e5a94c4c01ac79
Autor:
Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Jacob Menke, Joshua Schwieterman, Sekhu Ansari, Angela Reaves, Arhama Ahmed, Rammsha Shehzad, Areeba Khan, Nuha Syed, Noor Amir, Mark Wunderlich, Tahir Latif, William Seibel, Mohammad Azam
Publikováno v:
Blood Advances. 7:1460-1476
Despite significant advancements in developing selective FMS-like tyrosine kinase 3 (FLT3) inhibitors, resistance to treatment is common even on continued therapy. Acquisition of on-target mutations or adaptation to MAPK, JAK2, and ABL signaling path
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3f1efb6e215ddb3ea65af4de045b2fc
https://doi.org/10.1182/bloodadvances.2022007486
https://doi.org/10.1182/bloodadvances.2022007486
Autor:
Gabriel Gracia-Maldonado, Jason Clark, Matthew Burwinkel, Brenay Greenslade, Mark Wunderlich, Nathan Salomonis, Dario Leone, Evelina Gatti, Philippe Pierre, Ashish R. Kumar, Lynn H. Lee
Publikováno v:
Haematologica, Vol 107, Iss 4 (2021)
Although great advances have been made in understanding the pathobiology of mixed lineage leukemia-rearranged (MLL-r) leukemias, therapies for this leukemia have remained limited, and clinical outcomes remain bleak. In order to identify novel targets
Externí odkaz:
https://doaj.org/article/3a5c9617d03f4777999cbd2fb6ef2278